左旋咪唑上市后安全性再评价Ⅲ：风险预防对策  

Re-evaluation of Post-marketing Safety for LevamisoleⅢ:Risk Prevention Countermeasures

作　　者：杨学志[1] 郑荣远[1] 殷为勇[1] 朱振国[1] 朱英标[1] 曹立亚[2] 吴晔[2] 任经天[2] 

机构地区：[1]温州医学院附属第一医院神经内科浙江省神经药物流行病学研究中心,浙江温州325000 [2]国家食品药品监督管理局药品评价中心

出　　处：《药物流行病学杂志》2007年第6期335-337,共3页Chinese Journal of Pharmacoepidemiology

基　　金：系国家食品药品监督管理局药品评价中心委托与资助

摘　　要：目的:对左旋咪唑上市后文献进行分析评价,为药物监管措施提供参考。方法:整理、规纳、分析国内外左旋咪唑的不良反应报道。结果:左旋咪唑严重不良反应涉及多种器官和系统,其中以神经系统最为常见,包括脑炎综合征/脱髓鞘脑病、锥体外系反应。结论:药品监管部门、制药企业及临床医师应加强LMS ADR监测,规范药物临床使用,最大限度减少或避免严重不良反应的发生。Objective： To analyze and evaluate the literatures of post-marketlng levamisole and provide reasonable reference for drug supervision measures. Method ： The adverse reactions of levamisole reported in domestic and overseas literatures were analyzed. Result： The adverse reactions of levamisole were involved in multiple organs and systems, for example, nervous, dermatosis, digestive, hematological, cardiovascular and immune systems, and the nervous system was involved in the easiest way. Conclusion ： In order to decrease to a large extent or even avoid the occurrence of adverse reactions of levamisole, the drug administrative management, pharmaceutical companies and clinicians should strengthen the monitoring of levamisole＇s ADR, and the drug usage should be normally managed.

关 键 词：左旋咪唑 药物不良反应 药品上市后再评价 预防对策 

分 类 号：R978.63[医药卫生—药品]